JAKARTA - The revenue of PT Indofarma Tbk (INAF), a pharmaceutical company, was seen declining 60.56% year-on-year (yoy). This slippage then led to 124.37% decrease in its profit.

In the 2022 Financial Report quoted Monday (3/4), Agus Heru Darjono, President Director of INAF, mentioned that the net sales in 2022 clocked up to IDR 1.14 trillion, shifting down from IDR 2.90 trillion in 2021. It also recorded gross loss at IDR 110.10 billion in 2022 from the initial gross profit of IDR 451.65 billion in 2021, due to increased costs of sales.

The domestic sales shrank to IDR 1.12 trillion in 2022 from IDR 2.89 trillion in 2021. The sales number consisted of the ethical segment that decreased from IDR 1.11 trillion to IDR 524.66 billion, as well as health devices, clinical services, and others that declined from IDR 694.15 billion to IDR 139.67 billion. There was also the vaccine segment that shrank from IDR 924.76 billion to IDR 18.57 billion, and the over-the-counter drugs segment that depleted from IDR 52.53 billion to IDR 17.06 billion.

In the export market, INAF scored an increase in over-the-counter medicine sales from IDR 4.44 billion to IDR 7.55 billion, as well as in the ethical segment from IDR 2.44 billion to IDR 6.86 billion.

The operating loss was seen at IDR 479.54 billion, plummeting from the initial operating profit of IDR 51.97 billion. Its loss before taxes was at IDR 517.56 billion, massively shrinking from profit before taxes of IDR 8.77 billion in 2021. Thus, its current year's loss arrived at IDR 428.48 billion, worsening from IDR 37.57 billion of loss seen in 2021. (LK/ZH)